Orthofix raises sales guidance: Orthofix Medical stock sits 46.50 percent below its high

Published on 10/05/2026 at 03:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Orthofix targets USD 845 million-USD 855 million in 2026 sales. Orthofix Medical stock was last at USD 9.09 on October 2, 2026 versus USD 9.21.

OFIX, US68752M1080, Illustration mit AI erstellt.

Orthofix Medical (ISIN US68752M1080) raised its 2026 net sales guidance to USD 845 million-USD 855 million, while its Nasdaq quote was last at USD 9.09 on October 2, 2026, 46.50 percent below the USD 16.99 52-week high. As The Globe and Mail reported on October 1, 2026, the higher outlook followed second-quarter progress, reimbursement restoration and a European distributor arrangement.

Sales outlook moves higher

The new sales range implies 5.00 percent pro forma constant-currency growth at its midpoint, and the company also guided to adjusted EBITDA of USD 95 million-USD 98 million for fiscal year 2026, according to The Globe and Mail. The sales midpoint is USD 850 million, USD 7 million above the forecast issued in May, giving the guidance change a measurable operational anchor.

Orthofix's second-quarter 2026 revenue was USD 210.93 million against a USD 209.28 million consensus estimate. Its adjusted loss per share was USD 0.39, narrower than the USD 0.40 expected loss, according to Investing.com. The result combines better-than-expected sales with continuing losses, so the guidance increase depends on execution rather than reported profitability.

Analyst target stays at USD 13

Stifel maintained its Buy rating and USD 13.00 price target on September 15, 2026, citing profitable growth, improved commercial execution and the opportunity in Orthofix's 7D FLASH navigation product, as Investing.com reported. Smaller US spine distributors remain a stated challenge, while the global limb reconstruction segment grew 11.00 percent in the second quarter of 2026.

ToAlpha lists November 3, 2026, as the next reporting date for OFIX, with its company page identifying Orthofix as a Nasdaq medical-device issuer and showing the second-quarter filing date as August 5, 2026.

Nasdaq quote stays below yearly high

OFIX was last at USD 9.09 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, versus a USD 9.21 prior close. The same market snapshot showed a USD 367.4 million market capitalization and a USD 8.50-USD 16.99 52-week range.